cis-3,4-Methylene-heptanoylcarnitine: Characterization and verification of the C8:1 acylcarnitine in human urine

Yang, Shuming; Minkler, Paul E.; Hoppel, Charles L.

doi:10.1016/j.jchromb.2007.07.027

Cited by 25 publications

(27 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of HPLC separation in acylcarnitine analysis before detection has been shown to distinguish false positives from true positives (29 ), and our sequential ion-exchange/reversed-phase HPLC method adds even more selectivity (23 ). We synthesized more than 40 acylcarnitines [e.g., cis-3,4-methyleneheptanoylcarnitine (26 )] to be used as calibrators or internal standards and generated 42 individual multiplepoint calibration curves (Figs. 1 and 2) for MS/MS quantification of these acylcarnitines.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Quantification of Carnitine and Acylcarnitines in Biological Matrices by HPLC Electrospray Ionization– Mass Spectrometry

Minkler¹,

Stoll²,

Ingalls³

et al. 2008

Clinical Chemistry

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…More than 40 acylcarnitines were synthesized in our laboratory (24)(25)(26). We used Bovine Albumin Fraction V Solution (75 g/L in PBS; Invitrogen) as a proxy for biological samples.…”

Section: Chemicalsmentioning

confidence: 99%

Quantification of Carnitine and Acylcarnitines in Biological Matrices by HPLC Electrospray Ionization– Mass Spectrometry

Minkler¹,

Stoll²,

Ingalls³

et al. 2008

Clinical Chemistry

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, we used published methods for synthesis of acylcarnitines [37,38,39,40], and we prepared 66 different acylcarnitines, along with appropriate internal standards. Purification of synthesized acylcarnitines was accomplished using a two-step chromatographic process, combining cation-exchange solid-phase extraction (to remove unreacted acid) followed by preparative HPLC (to remove carnitine and synthetic impurities).…”

Section: Introductionmentioning

confidence: 99%

Quantitative acylcarnitine determination by UHPLC-MS/MS — Going beyond tandem MS acylcarnitine “profiles”

Minkler

Stoll

Ingalls

et al. 2015

Molecular Genetics and Metabolism

View full text Add to dashboard Cite

Tandem MS “profiling” of acylcarnitines and amino acids was conceived as a first-tier screening method, and its application to expanded newborn screening has been enormously successful. However, unlike amino acid screening (which uses amino acid analysis as its second-tier validation of screening results), acylcarnitine “profiling” also assumed the role of second-tier validation, due to the lack of a generally accepted second-tier acylcarnitine determination method. In this report, we present results from the application of our validated UHPLC-MS/MS second-tier method for the quantification of total carnitine, free carnitine, butyrobetaine, and acylcarnitines to patient samples with known diagnoses: malonic acidemia, short-chain acyl-CoA dehydrogenase deficiency (SCADD) or isobutyryl-CoA dehydrogenase deficiency (IBD), 3-methyl-crotonyl carboxylase deficiency (3-MCC) or β-ketothiolase deficiency (BKT), and methylmalonic acidemia (MMA). We demonstrate the assay’s ability to separate constitutional isomers and diastereomeric acylcarnitines and generate values with a high level of accuracy and precision. These capabilities are unavailable when using tandem MS “profiles”. We also show examples of research interest, where separation of acylcarnitine species and accurate and precise acylcarnitine quantification is necessary.

show abstract

“…Of note, only a few previous studies have investigated 2-octenoylcarnitine and no studies have examined its role in biliary tract cancer (44,45). In the present study, 2-octenoylcarnitine was markedly decreased in the bile from patients with biliary tract cancer and was examined as a potential biomarker for biliary tract cancer for the first time, although similar studies are required to repeat and verify the findings and to examine the detailed mechanism.…”

Section: Discussionmentioning

confidence: 59%

Identification of bile biomarkers of biliary tract cancer through a liquid chromatography/mass spectrometry-based metabolomic method

Cheng

Ding

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. The incidence and mortality rate of biliary tract cancer have been increasing worldwide; however, its diagnosis and prognosis have not improved in recent years. A novel approach, termed 'metabolomics', may have the potential to be developed as an effective diagnostic tool. The present study prospectively obtained bile samples from 115 individuals, including 32 patients with biliary tract cancer, 61 patients with benign biliary tract diseases and 22 normal controls. A liquid chromatography/mass spectrometry (LC/MS)-based approach was used to investigate the differences in bile samples between the three groups, followed by multivariate statistical analysis, which included partial least squares projection to latent structures with discriminant analysis (PLS-DA) and orthogonal projection to latent structures with discriminant analysis (OPLS-DA). The metabolomic 2D score plot and 3D plot revealed clear separation between the cancer, benign and normal control groups by PLS-DA. To further address the significant difficulties in clinically differentiating between biliary tract cancer and benign biliary tract diseases, OPLS-DA was performed to distinguish between the two disease groups and to select potential biomarkers. The cancer and benign groups were well differentiated. The metabolic analysis revealed significantly lower levels of lysophosphatidylcholine, phenylalanine, 2-octenoylcarnitine, tryptophan and significantly higher levels of taurine-and glycine-conjugated bile acids in the bile from patients with biliary tract cancer compared with those in the bile from patients with benign biliary tract disease. The present study suggested that an LC/MS-based metabolomic investigation provides a potent and promising approach for discriminating biliary tract cancer from benign biliary tract diseases and the identified specific metabolites may offer potential as novel biomarkers for the early detection of biliary tract cancer.

show abstract

cis-3,4-Methylene-heptanoylcarnitine: Characterization and verification of the C8:1 acylcarnitine in human urine

Cited by 25 publications

References 28 publications

Quantification of Carnitine and Acylcarnitines in Biological Matrices by HPLC Electrospray Ionization– Mass Spectrometry

Quantification of Carnitine and Acylcarnitines in Biological Matrices by HPLC Electrospray Ionization– Mass Spectrometry

Quantitative acylcarnitine determination by UHPLC-MS/MS — Going beyond tandem MS acylcarnitine “profiles”

Identification of bile biomarkers of biliary tract cancer through a liquid chromatography/mass spectrometry-based metabolomic method

Contact Info

Product

Resources

About